account_id none on file
legal_name MediWound Ltd.
ticker MDWD
cik 1593984
domain mediwound.com
linkedin_company_url https://www.linkedin.com/company/mediwound
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 1 filings 22 executives 1 family 0
why_nownone on file
calls
Second, The travel and visit requirements associated with the protocol created participation challenges for the older and medically complex VLU patient population. To support enrollment and reduce participation burden, we implemented patient assistance measures, including hotel reimbursements, transportation services, and facilitated access to enhanced care.
May 27, 2026 / receipt, needs a key / Ofer Gonen, CEO | earnings call 2026-05-27 | transcript 6afe0ebd-9c18-4a4f-a320-8a3cb837c9f7 | chars 3666-4026 | segment 3
filings
pay and travel expenses. We generally provide our employees with benefits and working conditions beyond the required minimums.
filing / Mar 5, 2026 / receipt
We leased approximately 4,000 square feet of additional office space in Gan Rave, Israel, pursuant to a two-year lease agreement that commenced on January 1, 2024 and was expired effective March 31, 2025.
filing / Mar 5, 2026 / receipt
our revenue growth, timing of milestone payments, the timing and extent of our spending on research and development efforts, and international
filing / Mar 5, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.
filing / Mar 5, 2026 / receipt
In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs.
filing / Mar 5, 2026 / receipt
6X Capacity Increase1
ir_statement / Sep 9, 2026 / receipt
Facility Scale-Up Supports Future Growth1
ir_statement / Sep 9, 2026 / receipt
Full manufacturing capacity anticipated in 2025/6
ir_statement / Sep 9, 2026 / receipt
Global demand exceeds current manufacturing capability 3X
ir_statement / Sep 9, 2026 / receipt
2. 2028 outlook includes revenue contribution related to EscharEx, subject to regulatory approval
ir_statement / Sep 9, 2026 / receipt
Commercial readiness/ execution
ir_statement / Sep 9, 2026 / receipt
Expanded facility
ir_statement / Sep 9, 2026 / receipt
executives
| Ofer Gonen | CEO | - | receipt |
familynone on file
upcoming
| 2026-11-19 | earnings call | scheduled | ir |
changesnone on file
mcp_package_hint
slug mediwound-ltd
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$